KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Other Non Operating Income (2019 - 2025)

Royalty Pharma's Other Non Operating Income history spans 7 years, with the latest figure at -$8.2 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 273.23% year-over-year to -$8.2 million; the TTM value through Dec 2025 reached -$14.3 million, down 839.07%, while the annual FY2025 figure was -$14.3 million, 839.07% down from the prior year.
  • Other Non Operating Income for Q4 2025 was -$8.2 million at Royalty Pharma, down from -$1.6 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $6.0 million in Q2 2024 and bottomed at -$18.3 million in Q4 2023.
  • The 5-year median for Other Non Operating Income is -$1.7 million (2023), against an average of -$2.9 million.
  • The largest annual shift saw Other Non Operating Income plummeted 4186.05% in 2022 before it skyrocketed 449.95% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at -$4.8 million in 2021, then skyrocketed by 75.83% to -$1.2 million in 2022, then crashed by 1471.5% to -$18.3 million in 2023, then skyrocketed by 88.04% to -$2.2 million in 2024, then tumbled by 273.23% to -$8.2 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Other Non Operating Income are -$8.2 million (Q4 2025), -$1.6 million (Q3 2025), and -$1.5 million (Q2 2025).